Cargando…
Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression
Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the real-world impact of durv...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453050/ https://www.ncbi.nlm.nih.gov/pubmed/37623024 http://dx.doi.org/10.3390/curroncol30080543 |
_version_ | 1785095825705140224 |
---|---|
author | Denault, Marie-Hélène Feng, Jamie Kuang, Shelley Shokoohi, Aria Leung, Bonnie Liu, Mitchell Berthelet, Eric Laskin, Janessa Sun, Sophie Zhang, Tina Ho, Cheryl Melosky, Barbara |
author_facet | Denault, Marie-Hélène Feng, Jamie Kuang, Shelley Shokoohi, Aria Leung, Bonnie Liu, Mitchell Berthelet, Eric Laskin, Janessa Sun, Sophie Zhang, Tina Ho, Cheryl Melosky, Barbara |
author_sort | Denault, Marie-Hélène |
collection | PubMed |
description | Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the real-world impact of durvalumab on OS according to PD-L1 tumor proportion score (TPS). Patients with stage III, unresectable NSCLC treated by CRT, with available PD-L1 TPS, from 1 March 2018 to 31 December 2020, at BC Cancer, British Columbia, Canada were included. Patients were divided into two groups, CRT + durvalumab and CRT alone. OS and PFS were analyzed in the PD-L1 ≥ 1% and <1% subgroups. A total of 134 patients were included in the CRT + durvalumab group and 117, in the CRT alone group. Median OS was 35.9 months in the CRT + durvalumab group and 27.4 months in the CRT alone group [HR 0.59 (95% CI 0.42–0.83), p = 0.003]. Durvalumab improved OS in the PD-L1 ≥ 1% [HR 0.53 (95% CI 0.34–0.81), p = 0.003, n = 175], but not in the <1% subgroup [HR 0.79 (95% CI 0.44–1.42), p = 0.4, n = 76]. This retrospective study demonstrates a statistically significant improvement in OS associated with durvalumab after CRT in PD-L1 ≥ 1%, but not PD-L1 < 1% NSCLC. Variables not accounted for may have biased the survival analysis. A prospective study would bring more insight. |
format | Online Article Text |
id | pubmed-10453050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104530502023-08-26 Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression Denault, Marie-Hélène Feng, Jamie Kuang, Shelley Shokoohi, Aria Leung, Bonnie Liu, Mitchell Berthelet, Eric Laskin, Janessa Sun, Sophie Zhang, Tina Ho, Cheryl Melosky, Barbara Curr Oncol Article Adjuvant durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). A post hoc exploratory analysis of PACIFIC revealed no OS benefit in the PD-L1 < 1% subgroup. This retrospective analysis assesses the real-world impact of durvalumab on OS according to PD-L1 tumor proportion score (TPS). Patients with stage III, unresectable NSCLC treated by CRT, with available PD-L1 TPS, from 1 March 2018 to 31 December 2020, at BC Cancer, British Columbia, Canada were included. Patients were divided into two groups, CRT + durvalumab and CRT alone. OS and PFS were analyzed in the PD-L1 ≥ 1% and <1% subgroups. A total of 134 patients were included in the CRT + durvalumab group and 117, in the CRT alone group. Median OS was 35.9 months in the CRT + durvalumab group and 27.4 months in the CRT alone group [HR 0.59 (95% CI 0.42–0.83), p = 0.003]. Durvalumab improved OS in the PD-L1 ≥ 1% [HR 0.53 (95% CI 0.34–0.81), p = 0.003, n = 175], but not in the <1% subgroup [HR 0.79 (95% CI 0.44–1.42), p = 0.4, n = 76]. This retrospective study demonstrates a statistically significant improvement in OS associated with durvalumab after CRT in PD-L1 ≥ 1%, but not PD-L1 < 1% NSCLC. Variables not accounted for may have biased the survival analysis. A prospective study would bring more insight. MDPI 2023-08-08 /pmc/articles/PMC10453050/ /pubmed/37623024 http://dx.doi.org/10.3390/curroncol30080543 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Denault, Marie-Hélène Feng, Jamie Kuang, Shelley Shokoohi, Aria Leung, Bonnie Liu, Mitchell Berthelet, Eric Laskin, Janessa Sun, Sophie Zhang, Tina Ho, Cheryl Melosky, Barbara Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression |
title | Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression |
title_full | Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression |
title_fullStr | Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression |
title_full_unstemmed | Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression |
title_short | Beyond PACIFIC: Real-World Outcomes of Adjuvant Durvalumab According to Treatment Received and PD-L1 Expression |
title_sort | beyond pacific: real-world outcomes of adjuvant durvalumab according to treatment received and pd-l1 expression |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453050/ https://www.ncbi.nlm.nih.gov/pubmed/37623024 http://dx.doi.org/10.3390/curroncol30080543 |
work_keys_str_mv | AT denaultmariehelene beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT fengjamie beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT kuangshelley beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT shokoohiaria beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT leungbonnie beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT liumitchell beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT bertheleteric beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT laskinjanessa beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT sunsophie beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT zhangtina beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT hocheryl beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression AT meloskybarbara beyondpacificrealworldoutcomesofadjuvantdurvalumabaccordingtotreatmentreceivedandpdl1expression |